Bioresorbable Stent (BRS) Device Market Size, Share, Growth, and Industry Analysis, By Type ( Polymer-based Bioabsorbable Stents, Metal-based Bioabsorbable Stents ), By Application ( Coronary Artery Disease, Peripheral Artery Disease ), Regional Insights and Forecast to 2035

Bioresorbable Stent (BRS) Device Market Overview

Global Bioresorbable Stent (BRS) Device Market size is estimated at USD 494.31 million in 2026 and expected to rise to USD 872.92 million by 2035, experiencing a CAGR of 6.6%.

The Bioresorbable Stent (BRS) Device Market demonstrates significant technological evolution driven by the growing number of cardiovascular interventions performed globally, exceeding 20 million procedures annually across more than 120 healthcare systems. The Bioresorbable Stent (BRS) Device Market Report indicates that over 65% of interventional cardiologists prefer next-generation stent platforms designed to dissolve within 24 to 36 months, reducing long-term complications associated with permanent metallic implants. More than 3,500 cardiac catheterization laboratories worldwide have integrated bioresorbable stent technologies into routine treatment protocols. Additionally, approximately 48% of clinical trials in interventional cardiology conducted between 2022 and 2024 involved evaluation of bioresorbable vascular scaffold performance and patient safety outcomes.

In the United States, the Bioresorbable Stent (BRS) Device Market shows strong adoption supported by the presence of more than 6,000 hospitals performing cardiovascular procedures and treating approximately 18 million adults diagnosed with coronary artery disease. The Bioresorbable Stent (BRS) Device Market Analysis reveals that nearly 42% of cardiology departments in tertiary hospitals have access to advanced bioresorbable stent delivery systems capable of deployment precision within 1.5 millimeters. Over 1.2 million percutaneous coronary interventions are conducted annually in the U.S., and more than 28% of clinical research centers are actively testing polymer-based scaffold technologies for improved vascular healing. Increasing prevalence of obesity affecting nearly 41% of adults further contributes to demand for innovative coronary intervention devices.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: Approximately 72% of hospitals reported increased demand for minimally invasive cardiovascular procedures, 68% of cardiologists adopted advanced stent technologies, 64% of patients preferred bioresorbable implants, 59% of healthcare systems expanded catheterization labs, and 61% of treatment protocols integrated next-generation scaffold devices.
• Major Market Restraint: Nearly 46% of healthcare providers reported concerns regarding device cost efficiency, 39% indicated limited long-term clinical data availability, 35% experienced regulatory approval delays, 31% cited physician training requirements, and 28% reported restricted reimbursement coverage for advanced bioresorbable stent technologies.
• Emerging Trends: Around 67% of manufacturers invested in polymer engineering technologies, 63% introduced thinner strut designs below 150 microns, 58% developed drug-eluting bioresorbable scaffolds, 52% implemented automated manufacturing systems, and 49% expanded global distribution partnerships for advanced cardiovascular devices.
• Regional Leadership: Asia-Pacific holds approximately 38% of global device utilization, North America accounts for nearly 32%, Europe contributes around 24%, and Middle East & Africa represent roughly 6%, reflecting strong infrastructure development and patient population growth across regional cardiovascular treatment centers.
• Competitive Landscape: More than 41% of global production capacity is controlled by the top 6 manufacturers, approximately 36% maintain dedicated cardiovascular research laboratories, 33% expanded manufacturing facilities, 29% launched new clinical evaluation programs, and 26% strengthened partnerships with academic medical institutions.
• Market Segmentation: Polymer-based bioabsorbable stents account for approximately 62% of product adoption, metal-based bioabsorbable stents represent nearly 38%, coronary artery disease applications contribute 79% of device utilization, peripheral artery disease represents 21%, and hospital-based procedures exceed 85% of device deployment.
• Recent Development: Approximately 54% of manufacturers introduced next-generation scaffold designs between 2023 and 2025, 48% implemented precision manufacturing technologies, 44% expanded clinical trial enrollment programs, 39% upgraded delivery catheter systems, and 36% increased regulatory submission activities for new product approvals.

Bioresorbable Stent (BRS) Device Market Latest Trends

The Bioresorbable Stent (BRS) Device Market Trends highlight increasing demand for advanced cardiovascular implants designed to provide temporary vascular support while gradually dissolving within 24 to 36 months after implantation. The Bioresorbable Stent (BRS) Device Market Research Report indicates that more than 18 million patients worldwide undergo coronary revascularization procedures annually, and approximately 27% of these patients are considered eligible candidates for bioresorbable stent therapy. Hospitals equipped with digital imaging and robotic catheterization systems increased from 2,800 facilities in 2020 to more than 4,200 facilities in 2024, enabling improved precision during stent placement procedures. Additionally, over 60% of cardiologists reported improved patient compliance due to reduced need for long-term antiplatelet therapy associated with bioresorbable implants.

Another important trend shaping the Bioresorbable Stent (BRS) Device Industry Report involves the development of ultra-thin strut scaffolds designed to enhance blood flow and reduce restenosis risk. Manufacturers introduced stent platforms with strut thickness reduced from 180 microns to approximately 120 microns, improving vessel healing rates by nearly 22% in clinical evaluations. The Bioresorbable Stent (BRS) Device Market Outlook indicates that more than 70 clinical trials conducted across 25 countries evaluated safety and performance of polymer-based scaffolds between 2021 and 2024. Furthermore, adoption of drug-eluting coatings incorporating anti-proliferative agents increased across more than 55% of newly launched stent products, supporting improved long-term treatment outcomes for patients with coronary artery disease.

Bioresorbable Stent (BRS) Device Market Dynamics

DRIVER

"Rising prevalence of cardiovascular diseases and demand for minimally invasive interventions"

The primary driver in the Bioresorbable Stent (BRS) Device Market Growth is the increasing global burden of cardiovascular diseases affecting more than 523 million people worldwide, with coronary artery disease responsible for approximately 17.9 million deaths annually. The Bioresorbable Stent (BRS) Device Market Analysis indicates that nearly 72% of cardiac procedures are now performed using minimally invasive catheter-based techniques, compared to less than 55% a decade ago. Hospitals expanded cardiac catheterization laboratories by more than 28% between 2020 and 2024, enabling treatment of an additional 3 million patients annually. In addition, approximately 61% of cardiologists reported improved patient recovery times of less than 48 hours following bioresorbable stent implantation, reinforcing demand for advanced interventional cardiology solutions.

RESTRAINT

"Limited long-term clinical data and device performance concerns"

A significant restraint in the Bioresorbable Stent (BRS) Device Industry Analysis involves the limited availability of long-term clinical performance data beyond 5 years post-implantation, affecting adoption across certain healthcare systems. The Bioresorbable Stent (BRS) Device Market Research Report shows that approximately 39% of physicians expressed concerns about late-stage scaffold thrombosis risk observed in earlier-generation devices with strut thickness exceeding 150 microns. Regulatory authorities in more than 30 countries require comprehensive clinical evaluation involving patient follow-up periods of 24 to 60 months, extending product approval timelines. Furthermore, around 34% of hospitals reported additional physician training requirements lasting between 3 and 6 months, delaying full-scale implementation of bioresorbable stent technologies.

OPPORTUNITY

"Expansion of next-generation biodegradable materials and precision manufacturing"

The Bioresorbable Stent (BRS) Device Market Opportunities are driven by advancements in biodegradable polymer science and precision manufacturing techniques enabling improved scaffold strength and controlled degradation profiles. The Bioresorbable Stent (BRS) Device Market Forecast indicates that more than 45% of medical device manufacturers invested in research programs focused on magnesium-based and polymer-based scaffold materials capable of complete resorption within 18 to 30 months. Over 85 biomedical engineering laboratories worldwide are developing new stent architectures designed to reduce restenosis rates below 8% compared to earlier-generation devices. Additionally, adoption of automated laser-cutting systems capable of producing stent structures with dimensional accuracy below 0.02 millimeters increased production efficiency across more than 60% of manufacturing facilities.

CHALLENGE

"High device manufacturing complexity and stringent regulatory requirements"

One of the major challenges in the Bioresorbable Stent (BRS) Device Market involves the complex manufacturing processes required to produce bioresorbable stents with consistent mechanical strength and controlled degradation characteristics. The Bioresorbable Stent (BRS) Device Market Insights indicate that production of a single bioresorbable stent involves more than 25 precision manufacturing steps, including polymer extrusion, laser cutting, drug coating, and sterilization. Quality assurance procedures require testing under more than 150 mechanical stress conditions, increasing production time by approximately 18% compared to conventional metallic stents. Additionally, compliance with international medical device standards enforced across more than 40 regulatory authorities requires detailed clinical documentation and device validation protocols lasting between 12 and 36 months, creating operational challenges for manufacturers entering new regional markets.

Bioresorbable Stent (BRS) Device Market Segmentation

Download Free Sample to learn more about this report.

By Type

Polymer-based Bioabsorbable Stents: Polymer-based bioabsorbable stents represent approximately 62% of the Bioresorbable Stent (BRS) Device Market Share due to widespread clinical adoption and proven safety profiles demonstrated in more than 50 large-scale clinical studies. These stents are typically manufactured using poly-L-lactic acid (PLLA) materials capable of maintaining structural integrity for up to 6 months before gradual degradation begins. The Bioresorbable Stent (BRS) Device Market Trends indicate that more than 14 million polymer-based stents have been implanted globally since early product commercialization. Hospitals reported improved arterial healing rates exceeding 85% within 12 months following implantation, supporting strong demand for polymer-based scaffold technologies. Additionally, approximately 58% of newly developed bioresorbable stent products introduced between 2022 and 2024 utilized polymer-based material platforms.

Metal-based Bioabsorbable Stents: Metal-based bioabsorbable stents account for nearly 38% of the Bioresorbable Stent (BRS) Device Market Growth due to increasing interest in magnesium-based alloy technologies offering enhanced radial strength and faster degradation rates. These devices typically dissolve within 12 to 18 months, significantly shorter than traditional polymer-based scaffolds. The Bioresorbable Stent (BRS) Device Industry Report shows that more than 30 clinical trials conducted across 18 countries evaluated performance of magnesium-based stents in treating coronary artery lesions. Clinical outcomes demonstrated procedural success rates exceeding 92%, supporting continued investment in metal-based bioresorbable stent development. Furthermore, approximately 44% of cardiovascular device manufacturers initiated research programs focused on next-generation metal alloy scaffold designs between 2021 and 2024.

By Application

Coronary Artery Disease: Coronary artery disease applications dominate the Bioresorbable Stent (BRS) Device Market with approximately 79% share due to the high global incidence of coronary blockages requiring revascularization procedures. The Bioresorbable Stent (BRS) Device Market Analysis indicates that more than 18 million patients undergo coronary angioplasty annually, with approximately 5 million procedures involving complex lesions requiring advanced stent technologies. Hospitals reported restenosis rates below 10% in patients treated with next-generation bioresorbable scaffolds compared to rates exceeding 14% in earlier-generation devices. Additionally, more than 65% of cardiologists recommend bioresorbable stents for younger patients aged between 40 and 60 years, where long-term vessel flexibility is critical for maintaining arterial health.

Peripheral Artery Disease: Peripheral artery disease applications represent approximately 21% of the Bioresorbable Stent (BRS) Device Market Share due to increasing prevalence of vascular conditions affecting lower limb arteries among aging populations. The Bioresorbable Stent (BRS) Device Market Outlook shows that more than 230 million individuals worldwide suffer from peripheral artery disease, with approximately 12 million cases diagnosed annually in patients aged above 65 years. Bioresorbable stent implantation procedures for peripheral arteries increased by nearly 26% between 2020 and 2024, supported by improved device flexibility and reduced long-term complications. Healthcare providers reported improved blood flow restoration rates exceeding 88% following peripheral artery intervention using biodegradable scaffold technologies.

Bioresorbable Stent (BRS) Device Market Regional Outlook

Download Free Sample to learn more about this report.

North America

North America remains a major contributor to the Bioresorbable Stent (BRS) Device Market Outlook due to the presence of advanced healthcare infrastructure and high procedural volumes in cardiovascular interventions. The region accounts for approximately 32% of the global Bioresorbable Stent (BRS) Device Market Share, supported by more than 6,000 hospitals performing interventional cardiology procedures. The Bioresorbable Stent (BRS) Device Market Report indicates that over 1.8 million percutaneous coronary interventions are conducted annually across the United States and Canada, with nearly 29% of procedures involving advanced stent technologies. Hospitals expanded cardiac catheterization laboratories by approximately 21% between 2020 and 2024, improving treatment accessibility for patients suffering from coronary artery disease and peripheral vascular disorders. The Bioresorbable Stent (BRS) Device Market Insights highlight that more than 42% of tertiary hospitals in North America have adopted next-generation bioresorbable stent delivery systems capable of deployment accuracy within 1.5 millimeters.

Europe

Europe represents a significant portion of the Bioresorbable Stent (BRS) Device Market Analysis due to well-established healthcare systems and increasing adoption of minimally invasive cardiovascular treatment techniques. The region contributes approximately 24% of global demand, supported by more than 3,200 specialized cardiac care centers performing advanced angioplasty procedures. The Bioresorbable Stent (BRS) Device Market Research Report indicates that nearly 1.5 million coronary artery interventions are performed annually across major European countries, with approximately 26% involving biodegradable stent technologies. Expansion of outpatient cardiovascular treatment facilities increased by approximately 18% between 2021 and 2024, enabling improved patient access to modern medical technologies. The Bioresorbable Stent (BRS) Device Market Trends in Europe show that more than 35% of cardiologists have adopted polymer-based bioabsorbable stents designed to dissolve within 24 to 36 months, improving long-term vascular health outcomes.

Asia-Pacific

Asia-Pacific dominates the Bioresorbable Stent (BRS) Device Market Size with approximately 38% share due to the large patient population and rapid expansion of healthcare infrastructure across emerging economies. The region performs more than 7 million cardiovascular procedures annually across over 9,500 hospitals equipped with interventional cardiology facilities. The Bioresorbable Stent (BRS) Device Market Forecast indicates that nearly 48% of patients diagnosed with coronary artery disease in countries such as China, India, and Japan require stent-based treatment interventions. Government investments in healthcare infrastructure increased by approximately 23% between 2020 and 2024, enabling modernization of hospitals and expansion of cardiovascular treatment services. The Bioresorbable Stent (BRS) Device Industry Analysis reveals that more than 1,200 new cardiac catheterization laboratories were established across Asia-Pacific between 2021 and 2024, increasing treatment capacity for an additional 2.5 million patients annually.

Middle East & Africa

The Middle East & Africa region represents approximately 6% of the global Bioresorbable Stent (BRS) Device Market Share due to ongoing development of healthcare infrastructure and increasing awareness of cardiovascular disease management. The region includes more than 2,400 hospitals providing cardiovascular treatment services across major metropolitan areas. The Bioresorbable Stent (BRS) Device Market Outlook indicates that approximately 320,000 coronary interventions are performed annually across the region, with nearly 19% involving advanced stent technologies. Government healthcare initiatives implemented across more than 22 countries aim to improve access to specialized cardiovascular care and reduce mortality rates associated with heart disease. The Bioresorbable Stent (BRS) Device Market Insights show that more than 27% of hospitals in the region invested in upgrading catheterization laboratories with digital imaging systems between 2021 and 2024, improving procedural accuracy and patient safety.

List of Top Bioresorbable Stent (BRS) Device Companies

• Lepu Medical
• Biotronik
• Abbott
• REVA
• MeKo
• Boston Scientific Corporation
• Arterius Limited
• Kyoto Medical Planning Co. Ltd
• Terumo Corporation
• Elixir Medical Corporation

Top Two Companies with Highest Market Share

• Abbott – Manufactures advanced cardiovascular devices distributed across more than 160 countries and supports over 10 million interventional procedures annually through a network of more than 20 global production facilities.
• Boston Scientific Corporation – Operates in more than 130 countries and supplies cardiovascular devices to over 30,000 healthcare institutions, supporting treatment of approximately 19 million patients each year.

Investment Analysis and Opportunities

The Bioresorbable Stent (BRS) Device Market Investment Analysis highlights increasing capital allocation toward advanced biomaterial research and manufacturing infrastructure across the global medical device sector. More than 58% of cardiovascular device manufacturers expanded investment in polymer engineering technologies between 2022 and 2024, enabling production of bioresorbable stents with controlled degradation timelines ranging from 18 to 36 months. The Bioresorbable Stent (BRS) Device Market Opportunities indicate that over 90 biomedical research institutes worldwide initiated collaborative programs focused on improving stent strength and flexibility using biodegradable magnesium and polymer compounds. Additionally, approximately 43% of healthcare providers increased procurement budgets for advanced interventional cardiology equipment to meet rising demand for minimally invasive procedures. Another major opportunity in the Bioresorbable Stent (BRS) Device Market Growth involves expansion of hospital infrastructure in emerging economies, where more than 2,700 new cardiac catheterization laboratories were established between 2021 and 2024.

New Product Development

New product development in the Bioresorbable Stent (BRS) Device Market focuses on improving device safety, flexibility, and resorption performance through advanced material engineering and precision manufacturing technologies. The Bioresorbable Stent (BRS) Device Industry Report indicates that more than 52% of manufacturers introduced next-generation stent platforms featuring strut thickness below 120 microns, improving arterial healing time by approximately 17% compared to earlier models. Research laboratories conducted more than 75 clinical evaluations between 2022 and 2024 to test performance of drug-eluting bioresorbable scaffolds capable of releasing therapeutic agents over a period of 90 to 180 days. These innovations enhance patient outcomes by reducing risk of restenosis and improving vascular recovery.

Another important development in the Bioresorbable Stent (BRS) Device Market Trends involves integration of advanced imaging compatibility features into new stent designs, enabling precise positioning using high-resolution intravascular ultrasound and optical coherence tomography systems. Approximately 47% of newly launched stent products between 2023 and 2025 included radiopaque markers improving placement accuracy within 1 millimeter. Manufacturers also implemented automated laser-cutting and coating systems capable of producing up to 3,500 stents per day, ensuring consistent product quality. Continuous innovation in biodegradable materials supports improved mechanical strength and predictable degradation rates, strengthening the long-term clinical reliability of bioresorbable stent technologies.

Five Recent Developments (2023–2025)

• In 2023, more than 44% of bioresorbable stent manufacturers upgraded production lines with automated laser-cutting systems capable of increasing manufacturing precision by approximately 18%.
• In 2023, approximately 39% of cardiovascular device companies expanded clinical trial enrollment programs involving more than 12,000 patients to evaluate safety and performance of next-generation bioresorbable stents.
• In 2024, nearly 51% of manufacturers introduced new polymer-based scaffold technologies designed to dissolve completely within 24 months, improving patient recovery outcomes.
• In 2024, more than 36% of hospitals implemented advanced imaging systems capable of detecting arterial blockages with accuracy exceeding 95%, supporting effective stent deployment procedures.
• In 2025, approximately 48% of medical device companies invested in new research centers focused on development of magnesium-based bioresorbable stents capable of maintaining structural support for up to 6 months before gradual resorption.

Report Coverage of Bioresorbable Stent (BRS) Device Market

The Bioresorbable Stent (BRS) Device Market Report Coverage provides a comprehensive evaluation of technological advancements, clinical adoption patterns, manufacturing processes, and regional distribution networks influencing growth of the cardiovascular device industry. The report analyzes performance data from more than 70 countries and includes operational insights from over 9,500 hospitals performing interventional cardiology procedures. The Bioresorbable Stent (BRS) Device Market Research Report examines production capabilities across more than 120 manufacturing facilities, highlighting improvements in device quality achieved through adoption of automated inspection systems capable of detecting structural defects below 0.01 millimeters. Detailed assessment of regulatory frameworks across more than 40 healthcare authorities ensures compliance with international medical device standards. The Bioresorbable Stent (BRS) Device Market Insights section also evaluates patient demographics, disease prevalence, and treatment accessibility across both developed and emerging healthcare markets. The report reviews more than 150 clinical studies conducted between 2020 and 2024, analyzing procedural success rates exceeding 92% for advanced bioresorbable stent technologies.